​

TScan Therapeutics (TCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TCRX Stock Forecast

TScan Therapeutics (TCRX) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $3.00 and a low of $3.00. This represents a 86.34% increase from the last price of $1.61.

$1 $2 $3 $4 $5 $6 $7 $8 $9 High: $3 Avg: $3 Low: $3 Last Closed Price: $1.61

TCRX Stock Rating

TScan Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

TCRX Price Target Upside V Benchmarks

TypeNameUpside
StockTScan Therapeutics86.34%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$3.00
Last Closing Price$1.61$1.61$1.61
Upside/Downside--86.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2544---8
May, 2544---8
Apr, 2544---8
Mar, 2544---8
Feb, 2544---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 07, 2025Barclays$3.00$1.9851.52%86.34%
May 16, 2024Justin ZelinBTIG$12.00$8.9334.38%645.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 07, 2025H.C. WainwrightBuyBuyhold
Aug 13, 2024WedbushBuyBuyhold
Jun 04, 2024NeedhamUnderperformUnderperformhold
May 16, 2024BTIGBuyinitialise
May 13, 2024WedbushBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.03$-2.74$-1.36$-1.14----
Avg Forecast$-6.39$-2.76$-1.54$-1.27$-1.28$-1.33$-1.12$-0.92
High Forecast$-0.26$-0.55$-1.32$-1.23$-1.09$-1.04$-0.81$-0.04
Low Forecast$-14.88$-5.33$-1.65$-1.31$-1.45$-1.57$-1.60$-1.90
Surprise %-68.23%-0.72%-11.69%-10.24%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.14M$13.54M$21.05M$2.82M----
Avg Forecast$11.32M$13.89M$16.86M$3.61M$6.98M$11.95M$26.31M$69.32M
High Forecast$22.88M$23.84M$18.54M$4.69M$12.73M$21.79M$47.97M$126.38M
Low Forecast$2.96M$5.34M$15.65M$2.92M$1.85M$3.16M$6.96M$18.33M
Surprise %-10.40%-2.58%24.84%-21.96%----

Net Income Forecast

$-1B $-800M $-600M $-400M $-200M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-48.63M$-65.81M$-89.22M$-127.50M----
Avg Forecast$-419.31M$-181.06M$-89.22M$-83.10M$-83.23M$-85.45M$-79.05M$-60.35M
High Forecast$-16.97M$-36.15M$-86.28M$-80.49M$-71.45M$-67.90M$-53.14M$-2.64M
Low Forecast$-976.21M$-349.53M$-108.21M$-85.71M$-95.02M$-103.00M$-104.96M$-124.93M
Surprise %-88.40%-63.65%-53.42%----

TCRX Forecast FAQ

Is TScan Therapeutics stock a buy?

TScan Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that TScan Therapeutics is a favorable investment for most analysts.

What is TScan Therapeutics's price target?

TScan Therapeutics's price target, set by 7 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $3 at the low end to $3 at the high end, suggesting a potential 86.34% change from the previous closing price of $1.61.

How does TScan Therapeutics stock forecast compare to its benchmarks?

TScan Therapeutics's stock forecast shows a 86.34% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for TScan Therapeutics over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is TScan Therapeutics’s EPS forecast?

TScan Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.28, marking a 12.28% increase from the reported $-1.14 in 2024. Estimates for the following years are $-1.33 in 2026, $-1.12 in 2027, and $-0.92 in 2028.

What is TScan Therapeutics’s revenue forecast?

TScan Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $6.98M, reflecting a 147.99% increase from the reported $2.82M in 2024. The forecast for 2026 is $11.95M, followed by $26.31M for 2027, and $69.32M for 2028.

What is TScan Therapeutics’s net income forecast?

TScan Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-83.231M, representing a -34.72% decrease from the reported $-127M in 2024. Projections indicate $-85.45M in 2026, $-79.048M in 2027, and $-60.352M in 2028.